Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations

Am J Hematol. 2009 Oct;84(10):629-30. doi: 10.1002/ajh.21508.

Authors

Ayalew Tefferi¹, Francesco Passamonti

Affiliation

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. tefferi.ayalew@mayo.edu

PMID: 19731306
DOI: 10.1002/ajh.21508

No abstract available

MeSH terms

Aspirin / administration & dosage
Aspirin / adverse effects
Aspirin / therapeutic use
Female
Heparin, Low-Molecular-Weight / administration & dosage
Heparin, Low-Molecular-Weight / adverse effects
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Hydroxyurea / administration & dosage
Hydroxyurea / adverse effects
Hydroxyurea / therapeutic use
Interferon Type I / administration & dosage
Interferon Type I / adverse effects
Interferon Type I / therapeutic use
Pregnancy
Pregnancy Complications / etiology
Pregnancy Complications / prevention & control*
Pregnancy Outcome
Recombinant Proteins
Thrombocythemia, Essential / complications
Thrombocythemia, Essential / drug therapy*

Substances

Heparin, Low-Molecular-Weight
Interferon Type I
Recombinant Proteins
Aspirin
Hydroxyurea